NO20022086L - Antidiabetisk formulering og fremgangsmåte - Google Patents

Antidiabetisk formulering og fremgangsmåte

Info

Publication number: NO20022086L
Authority: NO; Norway
Prior art keywords: antidiabetic; formulation; antidiabetic formulation
Prior art date: 1999-11-03

Application number

NO20022086A

Other languages

English (en)

Other versions

NO20022086D0 (no

Inventor

Beth Anne Piper

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-03

Filing date

2002-05-02

Publication date

2002-06-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23716278&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20022086(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-05-02 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2002-05-02 Publication of NO20022086D0 publication Critical patent/NO20022086D0/no

2002-06-24 Publication of NO20022086L publication Critical patent/NO20022086L/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO20022086A 1999-11-03 2002-05-02 Antidiabetisk formulering og fremgangsmåte NO20022086L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/432,465 US6586438B2 (en)	1999-11-03	1999-11-03	Antidiabetic formulation and method
PCT/US2000/028467 WO2001032158A2 (en)	1999-11-03	2000-10-13	Pharmaceutical composition comprising a combination of metformin and another antidiabetic agent

Publications (2)

Publication Number	Publication Date
NO20022086D0 NO20022086D0 (no)	2002-05-02
NO20022086L true NO20022086L (no)	2002-06-24

Family

ID=23716278

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20022086A NO20022086L (no)	1999-11-03	2002-05-02	Antidiabetisk formulering og fremgangsmåte

Country Status (34)

Country	Link
US (2)	US6586438B2 (no)
EP (1)	EP1253944A2 (no)
JP (2)	JP2003529551A (no)
KR (2)	KR20020050253A (no)
CN (3)	CN102283853A (no)
AR (1)	AR026355A1 (no)
AU (1)	AU781781B2 (no)
BG (2)	BG106732A (no)
BR (1)	BR0015295A (no)
CA (1)	CA2389931A1 (no)
CZ (2)	CZ20021547A3 (no)
DE (1)	DE60038455T2 (no)
EE (1)	EE05210B1 (no)
ES (1)	ES2302702T3 (no)
GE (2)	GEP20053539B (no)
HK (1)	HK1045655A1 (no)
HU (1)	HUP0300642A3 (no)
IL (3)	IL149138A0 (no)
LT (1)	LT5025B (no)
LV (1)	LV12907B (no)
MX (1)	MXPA02004290A (no)
MY (2)	MY125118A (no)
NO (1)	NO20022086L (no)
NZ (1)	NZ552074A (no)
PL (1)	PL366112A1 (no)
RO (1)	RO123109B1 (no)
RU (1)	RU2276604C2 (no)
SK (1)	SK4992002A3 (no)
TN (2)	TNSN00207A1 (no)
TW (1)	TWI241185B (no)
UA (2)	UA76706C2 (no)
UY (1)	UY26425A1 (no)
WO (1)	WO2001032158A2 (no)
ZA (2)	ZA200203367B (no)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7235627B2 (en) *	1996-08-30	2007-06-26	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6528486B1 (en)	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
US6414002B1 (en)	1999-09-22	2002-07-02	Bristol-Myers Squibb Company	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US20030040469A1 (en) *	2000-03-08	2003-02-27	Knudsen Liselotte Bjerre	Lowering serum lipids
AU2001241168B2 (en) *	2000-03-17	2005-06-16	Ajinomoto Co., Inc.	Drugs for complications of diabetes and neuropathy and utilization thereof
FR2816840B1 (fr)	2000-11-17	2004-04-09	Flamel Tech Sa	Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
US7062312B2 (en) *	2001-01-17	2006-06-13	Pediamed Pharmaceuticals, Inc.	Combination and method including a visual marker for determining compliance with a medication regimen
US20030022816A1 (en) *	2001-03-07	2003-01-30	Knudsen Liselotte Bjerre	Combined use of derivatives of GLP-1 analogs and PPAR ligands
US20020187926A1 (en) *	2001-03-07	2002-12-12	Knudsen Liselotte Bjerre	Combined use of derivatives of GLP-1 analogs and PPAR ligands
FR2825023B1 (fr) *	2001-05-23	2005-04-15	Flamel Tech Sa	Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
RU2004108219A (ru) *	2001-09-28	2005-03-10	Сан Фармасьютикл Индастриз Лимитид (In)	Лекарственная форма для лечения сахарного диабета
US6924311B2 (en) *	2001-10-17	2005-08-02	X-Ceptor Therapeutics, Inc.	Methods for affecting various diseases utilizing LXR compounds
US7183321B2 (en) *	2001-12-17	2007-02-27	Bristol-Myers Squibb Company	Antidiabetic formulation and method
EP1482919B1 (en)	2002-01-25	2007-05-02	Laboratorios Silanes, S.A. de C.V.	Pharmaceutical composition that is used to control blood glucose in patients with type 2 diabetes
US7906145B2 (en)	2002-04-09	2011-03-15	Flamel Technologies	Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
AU2002356419A1 (en)	2002-06-17	2003-12-31	Themis Laboratories Private Limited	Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
AU2003243929B2 (en) *	2002-07-04	2009-06-04	Zp Holding Spv K/S	GLP-1 and methods for treating diabetes
JP2004067575A (ja) *	2002-08-06	2004-03-04	Yaizu Suisankagaku Industry Co Ltd	糖尿病治療薬効果促進剤
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
SE526943C2 (sv) *	2002-08-26	2005-11-22	Indevex Ab	Födoämneskompositionsprodukt
UA80991C2 (en)	2002-10-07	2007-11-26		Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
US20040147564A1 (en) *	2003-01-29	2004-07-29	Rao Vinay U.	Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
ES2340997T3 (es) *	2003-07-24	2010-06-14	Wockhardt Limited	Composiciones orales para el tratamiento de diabetes.
EP1648933B1 (en) *	2003-07-25	2009-06-17	ConjuChem Biotechnologies Inc.	Long lasting insulin derivatives and methods thereof
US20050202063A1 (en) *	2003-08-26	2005-09-15	Ebn International Kft	Food product
WO2005065663A1 (en) *	2003-12-31	2005-07-21	Alpharma, Inc.	Rosiglitazone and metformin formulations
WO2005065654A2 (en) *	2003-12-31	2005-07-21	Alpharma, Inc.	Rosiglitazone formulations
EP1746993A4 (en) *	2004-04-29	2007-08-29	Andrx Labs Llc	METFORMIN COMPOSITIONS WITH CONTROLLED RELEASE
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
WO2006074278A2 (en) *	2005-01-05	2006-07-13	Mitsunori Ono	Compositions for treating diabetes or obesity
KR20070102694A (ko) *	2005-01-31	2007-10-19	아지노모토 가부시키가이샤	혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물
EP1889618A4 (en) *	2005-05-27	2010-11-24	Daiichi Sankyo Co Ltd	COMBINED MEDICATION FOR THE TREATMENT OF DIABETES
JP2009518429A (ja) *	2005-12-09	2009-05-07	メタプロテオミクス，エルエルシー	代謝症候群および糖尿病の治療のための抗炎症植物産物
KR20080081354A (ko) *	2005-12-28	2008-09-09	다케다 야쿠힌 고교 가부시키가이샤	당뇨병 치료제
FR2896157B1 (fr) *	2006-01-13	2008-09-12	Merck Sante Soc Par Actions Si	Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
BRPI0711558A2 (pt)	2006-05-04	2011-11-08	Boeringer Ingelheim Internat Gmbh	polimorfos
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
US20100008899A1 (en) *	2006-07-26	2010-01-14	Diamedica, Inc.	Methods of diagnosis and treatment for metabolic disorders
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
US20100136561A1 (en) *	2008-05-16	2010-06-03	Interleukin Genetics, Inc.	Genetic Markers for Weight Management and Methods of Use Thereof
KR20190016601A (ko)	2008-08-06	2019-02-18	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101189639B1 (ko) *	2008-12-15	2012-10-12	씨제이제일제당 (주)	메트포르민 및 α-글리코시다제 억제제를 포함하는 경구 제제 및 그 제조방법
ES2636087T3 (es)	2009-03-31	2017-10-05	Ligand Pharmaceuticals Inc.	Un antagonista de receptores de endotelina y angiotensina II de bifenilsulfonamida para tratar la glomeruloesclerosis
SG175390A1 (en)	2009-04-29	2011-12-29	Amarin Corp Plc	Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
AU2010241571B2 (en)	2009-04-29	2014-06-26	Amarin Pharmaceuticals Ireland Limited	Stable pharmaceutical composition and methods of using same
PL3318255T3 (pl)	2009-06-15	2021-09-06	Amarin Pharmaceuticals Ireland Limited	Kompozycje i sposoby leczenia udaru u pacjenta z jednoczesną terapią statyną
US20110009347A1 (en)	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
NZ599298A (en)	2009-11-27	2014-11-28	Boehringer Ingelheim Int	Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
CN101810628B (zh) *	2010-04-13	2012-05-23	北京四环科宝制药有限公司	二甲双胍格列吡嗪片及其制备方法
US9089538B2 (en)	2010-04-27	2015-07-28	Zealand Pharma A/S	Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
MX366325B (es)	2010-05-05	2019-07-05	Boehringer Ingelheim Int	Terapia de combinacion.
MX339570B (es)	2010-05-11	2016-05-31	Janssen Pharmaceutica Nv	Formulaciones farmaceuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienil-metilbenceno como inhibidores de transportadores de glucosa dependientes de sodio.
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
EP2646013A4 (en)	2010-11-29	2014-03-26	Amarin Pharma Inc	COMPOSITION WITH LOW IMPACT EFFECT AND METHOD FOR THE TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR DISEASES IN A PATIENT WITH FISH ALLERGY / SENSITIVITY
WO2012090225A2 (en) *	2010-12-29	2012-07-05	Nutracryst Therapeutics Private Limited	Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent
US9480663B2 (en)	2011-01-07	2016-11-01	Elcelyx Therapeutics, Inc.	Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en)	2012-01-06	2015-12-15	Elcelyx Therapeutics, Inc.	Compositions and methods of treating metabolic disorders
US8796338B2 (en)	2011-01-07	2014-08-05	Elcelyx Therapeutics, Inc	Biguanide compositions and methods of treating metabolic disorders
US11759441B2 (en)	2011-01-07	2023-09-19	Anji Pharmaceuticals Inc.	Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en)	2011-01-07	2017-02-21	Elcelyx Therapeutics, Inc.	Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US11974971B2 (en)	2011-01-07	2024-05-07	Anji Pharmaceuticals Inc.	Compositions and methods for treating metabolic disorders
WO2013103384A1 (en)	2012-01-06	2013-07-11	Elcelyx Therapeutics, Inc.	Biguanide compositions and methods of treating metabolic disorders
CN103597071A (zh)	2011-01-07	2014-02-19	埃尔舍利克斯治疗公司	基于化学感应受体配体的治疗
US9259477B2 (en)	2011-11-03	2016-02-16	Zealand Pharma A/S	GLP-1 receptor agonist peptide gastrin conjugates
US11291643B2 (en)	2011-11-07	2022-04-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
EP2800562A2 (en)	2012-01-06	2014-11-12	Elcelyx Therapeutics, Inc.	Compositions and methods for treating metabolic disorders
WO2013115742A1 (en) *	2012-01-31	2013-08-08	Mahmut Bilgic	Pharmaceutical composition comprising alpha-glucosidase inhibitor
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
US20130303462A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2013173923A1 (en)	2012-05-25	2013-11-28	Diamedica, Inc.	Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
EP2854841B1 (en)	2012-06-04	2017-02-22	Diamedica Inc.	Human tissue kallikrein 1 glycosylation isoforms
UA117103C2 (uk)	2012-07-23	2018-06-25	Зіленд Фарма А/С	Сполука, яка має активність агоніста глюкагону
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
US20140187633A1 (en)	2012-12-31	2014-07-03	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
KR101336499B1 (ko) *	2013-03-06	2013-12-03	씨제이제일제당 (주)	당뇨병의 예방 또는 치료용 복합 조성물
US20140271841A1 (en)	2013-03-15	2014-09-18	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US9585859B2 (en)	2013-10-10	2017-03-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
AU2014336098B2 (en)	2013-10-17	2018-05-10	Boehringer Ingelheim International Gmbh	Acylated glucagon analogues
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
KR102310392B1 (ko)	2013-11-06	2021-10-13	질랜드 파마 에이/에스	글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
WO2015067715A2 (en)	2013-11-06	2015-05-14	Zealand Pharma A/S	Gip-glp-1 dual agonist compounds and methods
WO2015128453A1 (en)	2014-02-28	2015-09-03	Boehringer Ingelheim International Gmbh	Medical use of a dpp-4 inhibitor
US10172818B2 (en)	2014-06-16	2019-01-08	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
MX381640B (es)	2014-10-29	2025-03-04	Zealand Pharma As	Metodos y compuestos agonistas de gip.
US10336802B2 (en)	2015-04-16	2019-07-02	Zealand Pharma A/S	Acylated glucagon analogue
CN109310697A (zh)	2016-06-10	2019-02-05	勃林格殷格翰国际有限公司	利格列汀和二甲双胍的组合
KR102502040B1 (ko)	2016-12-09	2023-02-24	질랜드 파마 에이/에스	아실화 glp-1/glp-2 이중 효능제
US11857608B2 (en)	2017-03-09	2024-01-02	Diamedica Inc.	Dosage forms of tissue kallikrein 1
WO2019046646A1 (en)	2017-08-30	2019-03-07	Whole Biome Inc.	METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
AU2019349563B2 (en)	2018-09-24	2023-06-08	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of cardiovascular events in a subject
CN113677355A (zh) *	2018-09-24	2021-11-19	潘德勒姆治疗公司	微生物组合物及使用方法
CN113648318B (zh) *	2020-05-12	2023-08-25	中国科学院上海营养与健康研究所	增强细胞产热和治疗疾病的应用
AU2022263358A1 (en)	2021-04-21	2023-11-30	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of heart failure

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3174901A (en)	1963-01-31	1965-03-23	Jan Marcel Didier Aron Samuel	Process for the oral treatment of diabetes
US4060634A (en)	1973-09-26	1977-11-29	Boehringer Mannheim G.M.B.H.	Rapidly resorbable glibenclamide
DE2348334C2 (de)	1973-09-26	1982-11-11	Boehringer Mannheim Gmbh, 6800 Mannheim	Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
NO154918C (no)	1977-08-27	1987-01-14	Bayer Ag	Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
EP0062704A1 (de)	1980-12-03	1982-10-20	Hoechst Aktiengesellschaft	Cyclopropancarbonsäureester-derivate als Mittel zum Bekämpfen von Magendasseln bei Equiden
JPS6051189A (ja)	1983-08-30	1985-03-22	Sankyo Co Ltd	チアゾリジン誘導体およびその製造法
US4916163A (en)	1985-06-04	1990-04-10	The Upjohn Company	Spray-dried lactose formulation of micronized glyburide
DE3543999A1 (de)	1985-12-13	1987-06-19	Bayer Ag	Hochreine acarbose
US5614492A (en)	1986-05-05	1997-03-25	The General Hospital Corporation	Insulinotropic hormone GLP-1 (7-36) and uses thereof
DE3833439A1 (de)	1988-10-01	1991-09-12	Hoechst Ag	Verfahren zur mikronisierung von glibenclamid
US5258185A (en) *	1989-08-23	1993-11-02	Bauer Kurt H	Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
DK36392D0 (da)	1992-03-19	1992-03-19	Novo Nordisk As	Anvendelse af kemisk forbindelse
DE4323636A1 (de)	1993-07-15	1995-01-19	Hoechst Ag	Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
TW438587B (en)	1995-06-20	2001-06-07	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it)	1995-11-14	1997-10-27	Gentili Ist Spa	Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
US6011049A (en) *	1997-02-19	2000-01-04	Warner-Lambert Company	Combinations for diabetes
US6153632A (en)	1997-02-24	2000-11-28	Rieveley; Robert B.	Method and composition for the treatment of diabetes
AU729529B2 (en) *	1997-06-06	2001-02-01	Depomed, Inc.	Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
WO1998056378A1 (en)	1997-06-13	1998-12-17	Novo Nordisk A/S	Novel niddm regimen
DE122007000054I1 (de)	1997-06-18	2007-12-13	Smithkline Beecham Plc	Behandlung der Diabetes mit Thiazolidindione und metformin
GB9715306D0 (en)	1997-07-18	1997-09-24	Smithkline Beecham Plc	Novel method of treatment
JP2001520193A (ja)	1997-10-17	2001-10-30	アヴェンティスファーマシューティカルズプロダクツインコーポレイテッド	キノリン誘導体の治療的使用
WO1999029314A1 (en)	1997-12-08	1999-06-17	Bristol-Myers Squibb Company	Novel salts of metformin and method
FR2774591B1 (fr)	1998-02-12	2000-05-05	Lipha	Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
FI111167B (fi) *	1998-02-24	2003-06-13	Kemira Chemicals Oy	Menetelmä lietteen säilyvyyden parantamiseksi
JP2002508162A (ja)	1998-02-27	2002-03-19	ノボノルディスクアクティーゼルスカブ	Ｎ末端を短縮したｇｌｐ−１誘導体
DK0974356T3 (da)	1998-07-15	2003-10-27	Merck Sante Sas	Tabletter omfattende en kombination af metformin og glibenclamid
DE69939481D1 (de)	1998-09-17	2008-10-16	Bristol Myers Squibb Co	Methode zur behandlung von diabetes die einen ap2-inhibitor und dazugehörige kombinationen verwendet
CO5200844A1 (es)	1999-09-17	2002-09-27	Novartis Ag	Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
EP2620443A1 (en)	2012-01-25	2013-07-31	Galecto Biotech AB	Novel galactoside inhibitors of galectins

1999
- 1999-11-03 US US09/432,465 patent/US6586438B2/en not_active Expired - Lifetime
- 1999-12-14 US US09/460,920 patent/US7598262B2/en not_active Expired - Lifetime
2000
- 2000-10-13 UA UA2002054480A patent/UA76706C2/uk unknown
- 2000-10-13 ES ES00972122T patent/ES2302702T3/es not_active Expired - Lifetime
- 2000-10-13 EP EP00970913A patent/EP1253944A2/en not_active Withdrawn
- 2000-10-13 DE DE60038455T patent/DE60038455T2/de not_active Expired - Lifetime
- 2000-10-13 BR BR0015295-1A patent/BR0015295A/pt not_active Application Discontinuation
- 2000-10-13 PL PL00366112A patent/PL366112A1/xx not_active Application Discontinuation
- 2000-10-13 UA UA2002054481A patent/UA75583C2/uk unknown
- 2000-10-13 GE GE4802A patent/GEP20053539B/en unknown
- 2000-10-13 CZ CZ20021547A patent/CZ20021547A3/cs unknown
- 2000-10-13 CA CA002389931A patent/CA2389931A1/en not_active Abandoned
- 2000-10-13 MX MXPA02004290A patent/MXPA02004290A/es not_active Application Discontinuation
- 2000-10-13 CN CN2011101796999A patent/CN102283853A/zh active Pending
- 2000-10-13 RU RU2002113764/15A patent/RU2276604C2/ru not_active IP Right Cessation
- 2000-10-13 GE GE4798A patent/GEP20053538B/en unknown
- 2000-10-13 NZ NZ552074A patent/NZ552074A/en not_active IP Right Cessation
- 2000-10-13 EE EEP200200241A patent/EE05210B1/xx not_active IP Right Cessation
- 2000-10-13 CZ CZ20021546A patent/CZ304090B6/cs not_active IP Right Cessation
- 2000-10-13 CN CNB008180288A patent/CN100386114C/zh not_active Expired - Lifetime
- 2000-10-13 CN CN2008100817553A patent/CN101273981B/zh not_active Expired - Lifetime
- 2000-10-13 HU HU0300642A patent/HUP0300642A3/hu unknown
- 2000-10-13 RO ROA200200560A patent/RO123109B1/ro unknown
- 2000-10-13 AU AU80229/00A patent/AU781781B2/en not_active Ceased
- 2000-10-13 SK SK499-2002A patent/SK4992002A3/sk not_active Application Discontinuation
- 2000-10-13 WO PCT/US2000/028467 patent/WO2001032158A2/en active IP Right Grant
- 2000-10-13 KR KR1020027005677A patent/KR20020050253A/ko not_active Application Discontinuation
- 2000-10-13 JP JP2001534363A patent/JP2003529551A/ja active Pending
- 2000-10-13 IL IL14913800A patent/IL149138A0/xx active IP Right Grant
- 2000-10-13 KR KR1020027005673A patent/KR100769786B1/ko active IP Right Grant
- 2000-10-24 MY MYPI20004996A patent/MY125118A/en unknown
- 2000-10-24 MY MYPI20004995A patent/MY136636A/en unknown
- 2000-10-27 TN TNTNSN00207A patent/TNSN00207A1/en unknown
- 2000-10-27 TW TW089122629A patent/TWI241185B/zh not_active IP Right Cessation
- 2000-10-27 TN TNTNSN00206A patent/TNSN00206A1/en unknown
- 2000-11-02 UY UY26425A patent/UY26425A1/es unknown
- 2000-11-03 AR ARP000105804A patent/AR026355A1/es unknown
2002
- 2002-04-15 IL IL149139A patent/IL149139A/en active IP Right Grant
- 2002-04-15 IL IL149138A patent/IL149138A/en not_active IP Right Cessation
- 2002-04-26 ZA ZA200203367A patent/ZA200203367B/xx unknown
- 2002-04-26 ZA ZA200203368A patent/ZA200203368B/xx unknown
- 2002-05-02 NO NO20022086A patent/NO20022086L/no unknown
- 2002-05-22 BG BG106732A patent/BG106732A/bg unknown
- 2002-05-22 BG BG106733A patent/BG65850B1/bg unknown
- 2002-05-24 LT LT2002062A patent/LT5025B/lt not_active IP Right Cessation
- 2002-06-03 LV LVP-02-93A patent/LV12907B/en unknown
- 2002-09-30 HK HK02107208.1A patent/HK1045655A1/zh unknown
2012
- 2012-09-25 JP JP2012211400A patent/JP2013028631A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
KR20020057994A (ko)	2002-07-12
ZA200203367B (en)	2003-09-10
US20020177602A1 (en)	2002-11-28
CZ304090B6 (cs)	2013-10-16
CN100386114C (zh)	2008-05-07
LV12907B (en)	2003-08-20
CN102283853A (zh)	2011-12-21
GEP20053538B (en)	2005-06-10
RU2002113764A (ru)	2004-03-20
RO123109B1 (ro)	2010-11-30
DE60038455D1 (de)	2008-05-08
SK4992002A3 (en)	2003-04-01
KR100769786B1 (ko)	2007-10-24
EE05210B1 (et)	2009-10-15
KR20020050253A (ko)	2002-06-26
NZ552074A (en)	2008-06-30
US6586438B2 (en)	2003-07-01
JP2013028631A (ja)	2013-02-07
NO20022086D0 (no)	2002-05-02
MXPA02004290A (es)	2003-02-12
AR026355A1 (es)	2003-02-05
RU2276604C2 (ru)	2006-05-20
LT2002062A (en)	2003-03-25
UA76706C2 (uk)	2006-09-15
TNSN00206A1 (en)	2005-11-10
MY125118A (en)	2006-07-31
HUP0300642A3 (en)	2006-05-29
CN101273981B (zh)	2011-01-26
TWI241185B (en)	2005-10-11
DE60038455T2 (de)	2009-04-23
HK1045655A1 (zh)	2002-12-06
BG106733A (bg)	2003-02-28
JP2003529551A (ja)	2003-10-07
CZ20021547A3 (cs)	2003-01-15
TNSN00207A1 (en)	2005-11-10
UA75583C2 (uk)	2006-05-15
BG106732A (bg)	2003-02-28
IL149138A0 (en)	2002-11-10
CN101273981A (zh)	2008-10-01
US20020183345A1 (en)	2002-12-05
AU8022900A (en)	2001-05-14
ES2302702T3 (es)	2008-08-01
ZA200203368B (en)	2003-09-02
PL366112A1 (en)	2005-01-24
AU781781B2 (en)	2005-06-16
LT5025B (lt)	2003-06-25
MY136636A (en)	2008-11-28
GEP20053539B (en)	2005-06-10
EE200200241A (et)	2003-12-15
IL149139A (en)	2011-11-30
EP1253944A2 (en)	2002-11-06
CN1414862A (zh)	2003-04-30
US7598262B2 (en)	2009-10-06
WO2001032158A3 (en)	2002-08-29
UY26425A1 (es)	2001-07-31
BG65850B1 (bg)	2010-03-31
IL149138A (en)	2007-12-03
BR0015295A (pt)	2003-06-24
WO2001032158A2 (en)	2001-05-10
CA2389931A1 (en)	2001-05-10
HUP0300642A2 (hu)	2003-07-28

Publication	Publication Date	Title
NO20022086L (no)	2002-06-24	Antidiabetisk formulering og fremgangsmåte
IS6385A (is)	2002-05-15	Ný notkun og nýjar N-asabísýkló-amíð afleiður
DK1454907T3 (da)	2009-03-09	Quninazolin og pyridopyrmidin-derivativer
NO20022334L (no)	2002-07-09	Ny sammensetning og anvendelse
NO20032753D0 (no)	2003-06-17	Forbindelse og anvendelse derav
DE60044764D1 (de)	2010-09-16	Durchgangs -Vorrichtung und -Verfahren
DE60031119D1 (de)	2006-11-16	Richtbohrvorrichtung und -verfahren
ATE311741T1 (de)	2005-12-15	Ernteverfahren und erntevorrichtung
DK1339292T3 (da)	2010-04-12	Sammensætning og fremgangsmåde
DE60014208D1 (de)	2004-11-04	Druckvorrichtung und -verfahren
DE50010609D1 (de)	2005-07-28	Sport-trainings-vorrichtung sowie sport-trainings-system
EP1455793A4 (en)	2007-03-07	ANTI-DIABETAL FORMULATION AND METHOD
NO20001485D0 (no)	2000-03-22	Redigeringsanordning og redigeringsfremgangsmåte
NO20002584L (no)	2000-11-20	Brønnreferanseapparat og fremgangsmÕte
NO20000188D0 (no)	2000-01-14	Fremgangsmåte og anordning for sidebroenntilknytning
DE60032898D1 (de)	2007-02-22	Arylthiazolidindion- und aryloxazolidinderivate
NO20016132D0 (no)	2001-12-14	Fremgangsmåte og anordning for batterier
DE60001791D1 (de)	2003-04-30	Bilderzeugungsgerät und -Verfahren
NO20005330D0 (no)	2000-10-23	Ulineær redigeringsanordning og ulineær redigeringsfremgangsmÕte
DE60028676D1 (de)	2006-07-27	Positionierungsverfahren und Positionierungsvorrichtung
DE60014484D1 (de)	2004-11-11	Anreiss-Vorrichtung und -Verfahren
NO20005763L (no)	2001-01-10	DHEA-sammensetning og fremgangsmåte
FI19991928L (fi)	2001-03-10	Punnitusmenetelmä ja -järjestely
NO20003268L (no)	2000-08-15	Hyperhydrert kitikolin, fremgangsmÕte og anvendelse
DE60041297D1 (de)	2009-02-26	Empfangsgerät und- Verfahren